Biotech Company With 140 Patents: #1 Stock of This Generation?

Today I received an email from Angel Publishing about “The #1 Stock of This Generation” and decided to take a closer look.

According to investment guru Keith Kohl, it’s a biotech company with 140 patents that has developed a pill that “could eradicate every single sign and symptom of aging in your body.”

He also claims that Jeff Bezos and Peter Thiel are betting on this company and that, as an investor, you could turn “a $500 stake into more than $1.5 million.”

What could it be? Well, that’s what I wanted to know. So I looked into the clues Kohl shared in the presentation, and in this post, I’ll show you what I found.

Reviewing Keith Kohl’s “End of Aging” Presentation

The “End of Aging” presentation kicks off with Keith Kohl showing a folder, which he claims contains 140 patents that “will soon alter the very fabric of the world as we know it.”

The company behind the patents, according to Kohl, is a “secretive company” located in a nondescript office park on the outskirts of San Francisco.

And he says the technology the company makes will “reshape human history more than the atom bomb, the combustion engine, and the electric lightbulb combined.”

As the presentation continued, Kohl revealed that the technology he’s talking about is a pill that “could eradicate every single sign and symptom of aging in your body.”

“Since the dawn of history, humanity has been searching for the key to everlasting life.”

[…]

“But finally, at last, our search has come to an end — all because of a small pill.”

Kohl showed a picture of a small yellowish-looking pill and cited a quote from the Guardian about how it could “spell the end of aging.”

I normally sit through the whole presentation, taking notes, before I begin researching. But in this case, my curiosity got the better of me. So I did some digging, and the Guardian quote Kohl cited appears to have been taken from this article about the science of senolytics.

The above article states that senolytics is an emerging area of anti-aging medicine centered around reducing the effects of old age.

And this is at the center of Keith Kohl’s “#1 stock of this generation” prediction… essentially that a pill his recommended company makes could eradicate the effects of aging.

How?

In short, Keith Kohl states that “cellular division is the root of all life as we know it.” When we’re young, he says that our cells are “constantly growing and dividing through a process called mitosis.” But as we get older, he says our cells stop dividing, and some become “zombie cells,” which he claims is “bad news” as it can “kick-start the aging process.”

“Scientists call them zombie cells.

Zombie cells don’t divide anymore, but they’re not totally dead yet, either.

Like the zombies you see in the movies, zombie cells are stuck inside you in a state of suspended animation.

It can happen to any cell that has reached the end of its life span.

This means if you’re over 40 years old, you probably have billions of zombie cells inside you right now. 

And this is bad news.”

I am not a medical professional or scientist, so I’m not sure how accurate Keith Kohl’s claims are regarding anti-aging. But this is what he claims in the presentation.

And to my surprise, according to the University of Minnesota, zombie cells are a real thing. The article I just linked to states that they’re called zombie cells because the cells are “damaged and refuse to die.”

In any case, Keith Kohl suggests that zombie cells aren’t good. And he says that the senolytics compounds inside the pill his recommended company makes “selectively target your old, damaged zombie cells, causing them to self-destruct.”

“Inside this patented pill is a special group of compounds called senolytics.

Seno is derived from the Latin word -senex, meaning old, and -lytic, meaning to destroy.

So the literal definition of senolytics is “old-destroying.”

And that’s exactly what these compounds do.

Once inside your body, senolytic compounds selectively target your old, damaged zombie cells, causing them to self-destruct.

Once the zombie cells have been destroyed…

Your cells can begin to divide again.

Your tissue can regenerate.

And you can actually start growing younger.”

So, to sum it up… Keith Kohl claims that a San Fransico-based biotech company has found a way to “make zombie cells self-destruct” and “completely erase every sign of aging from your body.” And it did so by discovering the “most powerful senolytic ever created.”

What company is he talking about?

Let’s take a look!

What Is “The #1 Stock of This Generation?”

As with virtually every presentation I review, Keith Kohl didn’t reveal the name of the company he’s teasing in the video. Instead, he details his pick in a report titled “The #1 Stock of This Generation: How You Could Ride the End of Aging to Enormous Stock Returns.”

But I looked into his clues.

And I think the company could be Unity Biotechnology (ticker: UBX).

This one was pretty easy to solve. All I did was search Google for a company that has patented 140 senolytic compounds because I figured not too many companies would have done that. And that search led me to this CNBC article about Unity Biotechnology.

In short, the above article talked about how Unity Biotechnology, which Jeff Bezos and Peter Thiel back, is working on a cure for aging.

However, according to the article, Unity Biotechnology isn’t focused on reversing aging itself. Instead, it designs treatments that can free a person of the diseases associated with aging, such as diabetes, heart disease, Alzheimer’s, and cancer.

In any case, the article revealed that Unity Biotechnology fits most of Keith Kohl’s initial clues. And my research suggests it’s a match on his other clues, too.

For example, the CEO and management team match Kohl’s description. According to a Form 10-K on the SEC website, the company holds “more than 140 patents and pending applications” in the U.S. and abroad. And the company’s market cap is currently about $41 million, which fits Kohl’s statement that its market cap is “only about $400 million.”

On that last point, it seems Kohl may have released this presentation in 2021 when the stock price was roughly ten times higher than it is right now. So, that explains why the market cap is lower than what he states in the presentation; the stock has recently sold off.

Another thing I wanted to address is what Keith Kohl said about the upcoming clinical trial. In short, he claims there’s a “groundbreaking” clinical trial in the works and points out that, when the results are positive, this “usually sends the company’s share price soaring.”

“A reality that will be here sooner than you know it, because this company is about to conclude a groundbreaking clinical trial that could prove humanity can vanquish aging forever.”

[…]

“All we’re waiting for now is for the early-stage data results to be announced.

Because when it comes to biotech, early-stage data are where the money’s made.

Only one-third of treatments ever make it past this stage.

But the ones that do pass the cut are almost guaranteed to make it to market, which means when Phase 1 and Phase 2 results are positive…

It usually sends the company’s share price soaring.”

I’m not sure what clinical trial he’s referring to.

However, a page on the company website details its active and upcoming clinical trials. And according to that page, the company is currently undertaking a “Phase 2a study” related to UBX1325, a potential treatment of age-related diseases of the eye.

In any case, “The #1 Stock of This Generation” (AKA biotech company with 140 patents) is Unity Biotechnology (UBX) because it fits the clues in Keith Kohl’s presentation.

How do you find out more?

There’s lots of information about Unity Biotechnology you can view online for free through a Google search. Or you could read the research report I mentioned earlier, where Keith Kohl shares all the details on his #1 company and why he’s bullish.

But there’s a catch with the second option. The only way to access Kohl’s report is to sign up for his Technology and Opportunity advisory service for $99.

Is it worth it?

To answer that, let’s look at what the service is about and how it works.

How Does Technology & Opportunity Work?

Technology and Opportunity is a stock advisory service edited by Keith Kohl of Angel Publishing, and it’s focused on the tech and biotech space.

The way it works is pretty straightforward; Kohl researches emerging technology and biotechnology trends and shares his top stock picks with subscribers each month.

The types of tech and biotech trends Kohl follows vary in scope, but the general idea is to help subscribers profit from small, unproven stocks before they go mainstream.

We’ve already discussed one of his picks in the biotech sector. But Keith Kohl has recommended numerous other stocks, some of which I’ve uncovered on this blog.

For example, as part of this service, Keith Kohl has recommended a company in the augmented reality space. And, more recently, a LiDAR stock (which I reveal here).

How have his picks performed?

I don’t have access to all of Kohl’s past recommendations. However, as I explain in my complete Technology and Opportunity review, he claims to have recommended numerous triple-digit stocks and a handful of quadruple-digit investments.

What do you get if you join?

The main feature of the service is the monthly newsletters. Each issue shows you what stock Kohl is most bullish on and breaks down his research on the company.

You also receive updates on his recommendations and access to his latest research reports. Including the one about his “#1 Investment of This Generation.”

How much does it cost?

A 12-month subscription to Technology and Opportunity costs $99. And according to the Angel Publishing website, the service has a 180-day refund policy in place.

So, is it worth it?

The types of investments Keith Kohl focuses on with this service are smaller, more speculative companies. So it could suit those interested in higher risk, higher reward opportunities. But it might not suit the more risk-averse investors.

Is Keith Kohl the Real Deal?

Keith Kohl is the chief investment strategist at Angel Publishing, a Baltimore-based financial publishing company. And according to the company website, his focus is to “uncover the technological forces that will shape our society.”

According to Kohl, his research involves meeting with CEOs and CTOs every day, researching patent filings, and networking with experts in different fields.

In the presentation, Kohl states that some of his top picks have included IRobot, Universal Display Corporation, and bitcoin.

Aside from tech and biotech, Kohl is pretty well-known for his work in the energy space. And he runs two other services for Angel Publishing: Energy Investor and Topline Trader.

From what I can tell, Keith Kohl is a real investment guru. Although that doesn’t mean all of his picks have worked out or will work in the future.

Bottom Line

The biotech company with 140 patents that Keith Kohl teases in “The #1 Investment of This Generation” presentation is Unity Biotechnology.

I say this because this company matches Kohl’s clues. For example, the clues about its anti-aging technology, management team, where it’s located, and who has backed it.

Is the presentation legit?

I wouldn’t expect to turn a “$500 stake into more than $1.5 million,” as Keith Kohl suggests. That might be possible, but in my opinion, that is a very bold prediction.

I also think some of what Kohl says about “curing aging forever” is overhyped. I’m not an expert on anti-aging by any stretch of the imagination, but some of his claims seem far-fetched. So, I recommend researching this topic yourself to see what you think.

As for the service itself, it’s not a scam. So, if you’re interested in smaller, more volatile stocks with strong upside potential and higher risk, it could be worth checking out. But as with any service, there’s no guarantee it will help you make money.

Anyway, that’s my take.

What about you? Do you think Kohl is onto something? Or is the whole “end of aging” thing an overblown marketing gimmick? Let me know in the comments below.